Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.
Press releases published on June 15, 2025

Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study New late-breaking data at EAACI showed Dupixent …

Communiqué : Dupixent a démontré sa supériorité par rapport au Xolair dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute 1ere étude respiratoire de ph4 en comparaison directe …
EAACI : Le Dupixent a démontré sa supériorité par rapport au Xolair (omalizumab) dans la rhinosinusite chronique avec polypes nasaux chez des patients atteints d’asthme coexistant dans la toute première étude respiratoire de phase 4 en comparaison directe …

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp …

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, …

ZA Miner Introduces Intelligent Cloud Mining Platform for 2025, Capitalizing on Bitcoin Halving Momentum and Market Growth
London, UK, June 15, 2025 (GLOBE NEWSWIRE) -- ZA Miner Introduces Intelligent Cloud Mining Platform for 2025, Capitalizing on Bitcoin Halving Momentum and Market Growth Platform leverages simplified mining contracts, smart infrastructure, and accessible …

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
– Pharmacology modeling data presented at the European Academy of Allergy …

D-Bal Max 2025: Exploring the Science and Safety behind a Popular And Legal Dianabol Steroid For Muscle Growth
Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced athletic performance and muscle growth, many fitness enthusiasts and bodybuilders turn to supplements. D-Bal Max has emerged as a noteworthy option that claims to replicate the muscle- …

Seventh Presale Phase: Bitcoin Solaris Nears Public Launch with 10,000 TPS and 21M Supply Cap
TALLINN, Estonia, June 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain built for speed, accessibility, and long-term sustainability, has officially entered the seventh phase of its token presale, with the public launch …

XRP News: Vaultro Finance Presale on XRP ledger Skyrockets Past 50%, As Investors Race to Own $VLT Token
SINGAPORE , June 15, 2025 (GLOBE NEWSWIRE) -- Vaultro Finance has just announced a landmark achievement in its public sale of the native utility token VLT. The $VLT presale Round has now achieved a 50% sale milestone, marking a pivotal moment in the …